Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation

A Japanese multicenter experience

Toru Ikegami, Yoshihide Ueda, Nobuhisa Akamatsu, Kohei Ishiyama, Ryoichi Goto, Akihiko Soyama, Kaori Kuramitsu, Masaki Honda, Masahiro Shinoda, Tomoharu Yoshizumi, Hideaki Okajima, Yuko Kitagawa, Yukihiro Inomata, Yonson Ku, Susumu Eguchi, Akinobu Taketomi, Hideki Ohdan, Norihiro Kokudo, Mitsuo Shimada, Katsuhiko Yanaga & 3 others Hiroyuki Furukawa, Shinji Uemoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

Original languageEnglish
Article numbere13109
JournalClinical Transplantation
Volume31
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Hepatitis C
Liver Transplantation
Hepacivirus
Galectin 3
Ribavirin
Interferons
Virus Diseases
Clinical Protocols
BMS-790052
asunaprevir
Multicenter Studies
Japan
Genotype
Simeprevir
Genome
Safety
Mutation
Infection

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation : A Japanese multicenter experience. / Ikegami, Toru; Ueda, Yoshihide; Akamatsu, Nobuhisa; Ishiyama, Kohei; Goto, Ryoichi; Soyama, Akihiko; Kuramitsu, Kaori; Honda, Masaki; Shinoda, Masahiro; Yoshizumi, Tomoharu; Okajima, Hideaki; Kitagawa, Yuko; Inomata, Yukihiro; Ku, Yonson; Eguchi, Susumu; Taketomi, Akinobu; Ohdan, Hideki; Kokudo, Norihiro; Shimada, Mitsuo; Yanaga, Katsuhiko; Furukawa, Hiroyuki; Uemoto, Shinji; Maehara, Yoshihiko.

In: Clinical Transplantation, Vol. 31, No. 11, e13109, 01.11.2017.

Research output: Contribution to journalArticle

Ikegami, T, Ueda, Y, Akamatsu, N, Ishiyama, K, Goto, R, Soyama, A, Kuramitsu, K, Honda, M, Shinoda, M, Yoshizumi, T, Okajima, H, Kitagawa, Y, Inomata, Y, Ku, Y, Eguchi, S, Taketomi, A, Ohdan, H, Kokudo, N, Shimada, M, Yanaga, K, Furukawa, H, Uemoto, S & Maehara, Y 2017, 'Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience', Clinical Transplantation, vol. 31, no. 11, e13109. https://doi.org/10.1111/ctr.13109
Ikegami, Toru ; Ueda, Yoshihide ; Akamatsu, Nobuhisa ; Ishiyama, Kohei ; Goto, Ryoichi ; Soyama, Akihiko ; Kuramitsu, Kaori ; Honda, Masaki ; Shinoda, Masahiro ; Yoshizumi, Tomoharu ; Okajima, Hideaki ; Kitagawa, Yuko ; Inomata, Yukihiro ; Ku, Yonson ; Eguchi, Susumu ; Taketomi, Akinobu ; Ohdan, Hideki ; Kokudo, Norihiro ; Shimada, Mitsuo ; Yanaga, Katsuhiko ; Furukawa, Hiroyuki ; Uemoto, Shinji ; Maehara, Yoshihiko. / Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation : A Japanese multicenter experience. In: Clinical Transplantation. 2017 ; Vol. 31, No. 11.
@article{233d4ee459a742b7bdeb1b2d327d52a8,
title = "Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience",
abstract = "The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1{\%}) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2{\%}) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4{\%}) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3{\%}) patients, it was achieved in only two (16.7{\%}) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4{\%}. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.",
author = "Toru Ikegami and Yoshihide Ueda and Nobuhisa Akamatsu and Kohei Ishiyama and Ryoichi Goto and Akihiko Soyama and Kaori Kuramitsu and Masaki Honda and Masahiro Shinoda and Tomoharu Yoshizumi and Hideaki Okajima and Yuko Kitagawa and Yukihiro Inomata and Yonson Ku and Susumu Eguchi and Akinobu Taketomi and Hideki Ohdan and Norihiro Kokudo and Mitsuo Shimada and Katsuhiko Yanaga and Hiroyuki Furukawa and Shinji Uemoto and Yoshihiko Maehara",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/ctr.13109",
language = "English",
volume = "31",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation

T2 - A Japanese multicenter experience

AU - Ikegami, Toru

AU - Ueda, Yoshihide

AU - Akamatsu, Nobuhisa

AU - Ishiyama, Kohei

AU - Goto, Ryoichi

AU - Soyama, Akihiko

AU - Kuramitsu, Kaori

AU - Honda, Masaki

AU - Shinoda, Masahiro

AU - Yoshizumi, Tomoharu

AU - Okajima, Hideaki

AU - Kitagawa, Yuko

AU - Inomata, Yukihiro

AU - Ku, Yonson

AU - Eguchi, Susumu

AU - Taketomi, Akinobu

AU - Ohdan, Hideki

AU - Kokudo, Norihiro

AU - Shimada, Mitsuo

AU - Yanaga, Katsuhiko

AU - Furukawa, Hiroyuki

AU - Uemoto, Shinji

AU - Maehara, Yoshihiko

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

AB - The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

UR - http://www.scopus.com/inward/record.url?scp=85030242819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030242819&partnerID=8YFLogxK

U2 - 10.1111/ctr.13109

DO - 10.1111/ctr.13109

M3 - Article

VL - 31

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 11

M1 - e13109

ER -